Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...

Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently received ...

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...

In a report released today, Boobalan Pachaiyappan from Roth MKM reiterated a Buy rating on Entrada Therapeutics Inc (TRDA – Research Report), ...

Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and ...

Shares of Entrada Therapeutics rose after regulators removed a clinical hold and said its lead product candidate could be studied as a treatment for Duchenne muscular dystrophy. The stock was up 9.5% ...

Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy - - Follows recently received ...

New rivalries, fresh faces, line-up changes and much more. Gear up for Buriram as MotoGP blasts back into action ...

Matchday 26 of the Premier League is about to deliver one of the most thrilling and decisive encounters of the season.

Providing expert witness testimony and detailed reports to assist in legal cases. Forensic engineering is a critical ...

Interested parties may access the live and archived webcasts under the "Investors” section of the company's website at: https ...

Phase 1b US study planned for 2026, as company competes with NS Pharma and Avidity Biosciences in exon 44 space ...